Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study

• Published in: British journal of cancer Vol. 95; no. 3; pp. 260 - 265
• Main Authors: BLACKSTOCK, A. W, MORNEX, F, TEPPER, J. E, PARTENSKY, C, DESCOS, L, CASE, L. D, MELIN, S. A, LEVINE, E. A, MISHRA, G, LIMENTANI, S. A, KACHNIC, L. A
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 07.08.2006
• Subjects: Adenocarcinoma - surgery; Adult; Aged; Biological and medical sciences; Chemotherapy, Adjuvant; Clinical Study; Combined Modality Therapy; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gemcitabine; Humans; Injections, Intravenous; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - therapy; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - radiotherapy; Pancreatic Neoplasms - surgery; Recurrence; Survival Rate; Treatment Outcome; Tumors; Antineoplastic agent; Human; Gemcitabine; Concurrent; Malignant tumor; Radiotherapy; Chemotherapy; Cancerology; Antimetabolic; Pancreas cancer; Phase II trial; Digestive diseases; Pyrimidine derivatives; pancreatic; Adjuvant; Combined treatment; Fluorine Organic compounds; Pyrimidine nucleoside; chemoradiation; Pancreatic disease

The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (4...